JCR Pharmaceuticals Co., Ltd. 4552
TSE · Japan · Health Technology
¥484.00-18.00 (-3.59%)
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
MILAN & HYOGO, Japan, October 02, 2026--Italfarmaco and JCR announced an exclusive license agreement to develop and commercialize JR-141 in the United States, Europe, and Latin America.
HYOGO, Japan, September 28, 2026--The Ministry of Health, Labour and Welfare of Japan granted orphan drug designation to givinostat, an investigational drug for the treatment of DMD.
TOKYO & HYOGO, Japan, September 11, 2026--JCR and MEDIPAL announced that the first participant has been dosed in the global Phase I/II trial of JR-446 for mucopolysaccharidosis type IIIB.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.